What's new — Colorectal adenocarcinoma¶
Generated 2026-11-01 from the publication dates of every paper cited in this condition's pages.
This page answers a different question from the curation log. The log says when we last edited a page; this says how recent the evidence on those pages is — so you can tell settled ground from a field that is actively moving, and jump straight to what has emerged lately.
How much of this condition's evidence is recent¶
| Published within | Cited papers |
|---|---|
| last week | 0 |
| last month | 6 |
| last 2 months | 14 |
| last 3 months | 15 |
| last 6 months | 26 |
| last year | 33 |
| older than a year | 286 |
Counts are cumulative: a paper from last week also counts inside "last month". Dates are PubMed publication or e-publication dates, so a paper may have appeared online before its journal issue.
Newest evidence first¶
The most recent cited papers, with the pages that use them.
| Published | Paper | Cited on |
|---|---|---|
| 2026-10-02 | Clinical Complete Response with Dostarlimab Monotherapy in dMMR/MSI-H Locally Advanced Rectal Cancer: First Results from the Global AZUR-1 Trial — Ann Oncol ([PMID 42927858](https://pubmed.ncbi.nlm.nih.gov/42927858/){target="_blank" rel="noopener"}) | clinical-trials-landscape, localized-rectal-cancer |
| 2026-10-02 | A randomised phase III trial of adjuvant treatment intensification with mFOLFIRINOX versus mFOLFOX6 in high-risk stage III colon cancer: Results of the international IROCAS study — Ann Oncol ([PMID 42927853](https://pubmed.ncbi.nlm.nih.gov/42927853/){target="_blank" rel="noopener"}) | clinical-trials-landscape, localized-colon-cancer |
| 2026-10-02 | Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial — Lancet Oncol ([PMID 42927765](https://pubmed.ncbi.nlm.nih.gov/42927765/){target="_blank" rel="noopener"}) | clinical-trials-landscape, localized-rectal-cancer |
| 2026-10-02 | Final results of nivolumab plus ipilimumab versus nivolumab or chemotherapy in microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer from CheckMate 8HW — Ann Oncol ([PMID 42926106](https://pubmed.ncbi.nlm.nih.gov/42926106/){target="_blank" rel="noopener"}) | clinical-trials-landscape, metastatic-systemic-therapy, precision-oncology |
| 2026-10-02 | 14-day versus 28-day trifluridine-tipiracil plus bevacizumab for refractory metastatic colorectal cancer (PRABITAS): a pragmatic, multicentre, open-label, randomised, phase 3, non-inferiority trial in Japan — Lancet ([PMID 42925880](https://pubmed.ncbi.nlm.nih.gov/42925880/){target="_blank" rel="noopener"}) | metastatic-systemic-therapy |
| 2026-10-02 | Disease-free survival and overall survival after neoadjuvant immunotherapy in mismatch repair-deficient colon cancer in the Netherlands: results of the single-arm, multicentre, phase 2, NICHE-2 trial — Lancet ([PMID 42906564](https://pubmed.ncbi.nlm.nih.gov/42906564/){target="_blank" rel="noopener"}) | clinical-trials-landscape, localized-colon-cancer |
| 2026-09-17 | Colonoscopy Intervals and Colorectal Cancer Incidence after Adenoma Removal — N Engl J Med ([PMID 42748427](https://pubmed.ncbi.nlm.nih.gov/42748427/){target="_blank" rel="noopener"}) | screening-and-early-detection |
| 2026-09-03 | Serrated Polyposis Syndrome: A Review and Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer — Gastroenterology ([PMID 42814045](https://pubmed.ncbi.nlm.nih.gov/42814045/){target="_blank" rel="noopener"}) | guidelines |
| 2026-09-02 | Microwave ablation versus stereotactic body radiotherapy for oligometastatic colorectal liver metastases (LAVA-CRLM): a prospective, randomised, phase II trial — Lancet Reg Health Eur ([PMID 42829779](https://pubmed.ncbi.nlm.nih.gov/42829779/){target="_blank" rel="noopener"}) | liver-and-lung-metastasis |
| 2026-09-02 | Erratum: Five-Year Outcomes of Short-Term Radiotherapy Plus Chemotherapy Versus Long-Term Chemoradiotherapy for Locally Advanced Rectal Cancer: Updated Results of the STELLAR Trial — J Clin Oncol ([PMID 42789827](https://pubmed.ncbi.nlm.nih.gov/42789827/){target="_blank" rel="noopener"}) | localized-rectal-cancer |
| 2026-09-02 | Aspirin after curative-intent treatment of colorectal cancer liver metastases (ASAC): a multicentre, phase 3, randomised, double-blind, placebo-controlled trial — Lancet Gastroenterol Hepatol ([PMID 42777749](https://pubmed.ncbi.nlm.nih.gov/42777749/){target="_blank" rel="noopener"}) | clinical-trials-landscape, liver-and-lung-metastasis |
| 2026-09-01 | ACG Clinical Guideline: Diagnosis and Management of Adenomatous Colorectal Polyposis Syndromes — Am J Gastroenterol ([PMID 42683623](https://pubmed.ncbi.nlm.nih.gov/42683623/){target="_blank" rel="noopener"}) | guidelines |
| 2026-09-01 | Addition of High-Dose Vitamin D3 to Standard Treatment in Patients With Metastatic Colorectal Cancer: The SOLARIS Randomized Clinical Trial (Alliance A021703) — JAMA ([PMID 42545685](https://pubmed.ncbi.nlm.nih.gov/42545685/){target="_blank" rel="noopener"}) | clinical-trials-landscape, metastatic-systemic-therapy |
| 2026-09-01 | Circulating Tumor DNA Status and Adjuvant Chemotherapy in Resected Colorectal Liver Metastases — JAMA Oncol ([PMID 42397676](https://pubmed.ncbi.nlm.nih.gov/42397676/){target="_blank" rel="noopener"}) | biomarkers-and-liquid-biopsy, liver-and-lung-metastasis |
| 2026-08-02 | Chemoradiotherapy versus short-course radiotherapy for response-adapted organ preservation in early-stage and intermediate-stage rectal cancer (STAR-TREC): 12-month results of an international, multicentre, open-label, parallel-group, randomised, phase 2/3 trial — Lancet Oncol ([PMID 42633754](https://pubmed.ncbi.nlm.nih.gov/42633754/){target="_blank" rel="noopener"}) | clinical-trials-landscape, localized-rectal-cancer |
| 2026-08-01 | A blood-based test for detection of advanced adenomas and colorectal cancer (DENEB): a multicentre diagnostic accuracy study — Lancet Gastroenterol Hepatol ([PMID 42575119](https://pubmed.ncbi.nlm.nih.gov/42575119/){target="_blank" rel="noopener"}) | screening-and-early-detection |
| 2026-07-09 | Aspirin for cancer prevention in individuals with Lynch syndrome: first results from the CaPP3 multicentre, randomised, double-blind, non-inferiority trial — Lancet Gastroenterol Hepatol ([PMID 42425127](https://pubmed.ncbi.nlm.nih.gov/42425127/){target="_blank" rel="noopener"}) | hereditary-syndromes-and-genetics |
| 2026-07-02 | COMMIT: A Randomized Study of mFOLFOX6/Bevacizumab/Atezolizumab or Atezolizumab Alone as First-Line Treatment of Deficient DNA Mismatch Repair Metastatic Colorectal Cancer — J Clin Oncol ([PMID 42525921](https://pubmed.ncbi.nlm.nih.gov/42525921/){target="_blank" rel="noopener"}) | clinical-trials-landscape, metastatic-systemic-therapy, precision-oncology |
| 2026-07-02 | Disparities in colonoscopy adherence and neoplasia detection after positive fecal immunochemical test: a retrospective matched cohort study — Cancer Causes Control ([PMID 42517977](https://pubmed.ncbi.nlm.nih.gov/42517977/){target="_blank" rel="noopener"}) | screening-and-early-detection |
| 2026-07-02 | Common analysis pitfalls in longitudinal ctDNA studies: lead time, sensitivity and immortal time bias — EBioMedicine ([PMID 42508231](https://pubmed.ncbi.nlm.nih.gov/42508231/){target="_blank" rel="noopener"}) | biomarkers-and-liquid-biopsy |
| 2026-07-02 | Five-Year Outcomes of Short-Term Radiotherapy Plus Chemotherapy Versus Long-Term Chemoradiotherapy for Locally Advanced Rectal Cancer: Updated Results of the STELLAR Trial — J Clin Oncol ([PMID 42507974](https://pubmed.ncbi.nlm.nih.gov/42507974/){target="_blank" rel="noopener"}) | localized-rectal-cancer |
| 2026-07-02 | Total Neoadjuvant Therapy With Long-Course Radiotherapy Versus Chemoradiotherapy in High-Risk Locally Advanced Rectal Cancer (TNTCRT): A Multicenter, Randomized, Phase III Trial — J Clin Oncol ([PMID 42492015](https://pubmed.ncbi.nlm.nih.gov/42492015/){target="_blank" rel="noopener"}) | clinical-trials-landscape, localized-rectal-cancer |
| 2026-07-02 | UGT1A1 genotype testing for irinotecan: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx) — Br J Clin Pharmacol ([PMID 42389808](https://pubmed.ncbi.nlm.nih.gov/42389808/){target="_blank" rel="noopener"}) | guidelines, red-flags-and-safety-concerns |
| 2026-07-01 | Thermal ablation versus liver resection for small colorectal liver metastases (≤ 3 cm): a systematic review and meta-analysis of randomized and propensity score-matched studies — Surg Endosc ([PMID 42463528](https://pubmed.ncbi.nlm.nih.gov/42463528/){target="_blank" rel="noopener"}) | liver-and-lung-metastasis |
| 2026-07-01 | Global cancer statistics 2024: GLOBOCAN estimates of incidence and mortality worldwide for 34 cancers in 186 countries — CA Cancer J Clin ([PMID 42417444](https://pubmed.ncbi.nlm.nih.gov/42417444/){target="_blank" rel="noopener"}) | epidemiology-and-burden |
| 2026-05-05 | Long-term effects of colonoscopy screening on colorectal cancer incidence and mortality: a multicountry, population-based randomised controlled trial — Lancet ([PMID 42102826](https://pubmed.ncbi.nlm.nih.gov/42102826/){target="_blank" rel="noopener"}) | screening-and-early-detection |
| 2026-05-01 | Colorectal cancer screening: An update to the American Cancer Society guideline, 2026 — CA Cancer J Clin ([PMID 42200680](https://pubmed.ncbi.nlm.nih.gov/42200680/){target="_blank" rel="noopener"}) | guidelines, screening-and-early-detection |
| 2026-04-01 | Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up — Ann Oncol ([PMID 41990853](https://pubmed.ncbi.nlm.nih.gov/41990853/){target="_blank" rel="noopener"}) | guidelines |
| 2026-04-01 | Interventions for Increasing Colorectal Cancer Screening Uptake: A Systematic Review and Network Meta-Analysis — Gastroenterology ([PMID 41932450](https://pubmed.ncbi.nlm.nih.gov/41932450/){target="_blank" rel="noopener"}) | screening-and-early-detection |
| 2026-01-02 | ESMO Clinical Practice Guideline Express Update on the adoption of physical exercise in patients with localised colon cancer — ESMO Open ([PMID 41741110](https://pubmed.ncbi.nlm.nih.gov/41741110/){target="_blank" rel="noopener"}) | guidelines |
| 2026-01-02 | Circulating Tumor DNA as a Biomarker for Recurrence After Curative Resection of Colorectal Cancer Liver Metastases: A Systematic Review and Meta-Analysis — Clin Colorectal Cancer ([PMID 41723037](https://pubmed.ncbi.nlm.nih.gov/41723037/){target="_blank" rel="noopener"}) | biomarkers-and-liquid-biopsy |
| 2026-01-02 | Psychosocial effects and quality of life after stoma surgery: systematic review and qualitative meta-synthesis — BMC Psychol ([PMID 41578363](https://pubmed.ncbi.nlm.nih.gov/41578363/){target="_blank" rel="noopener"}) | patient-experience-and-advocacy |
| 2025-11-01 | Systemic chemotherapy for patients with resectable or resected colorectal cancer liver metastases: An individual patient data meta-analysis — Eur J Cancer ([PMID 41197289](https://pubmed.ncbi.nlm.nih.gov/41197289/){target="_blank" rel="noopener"}) | liver-and-lung-metastasis |
Trials — what has moved¶
39 registered trials are cited by this condition's pages. Registry records were re-checked live when this page was generated, so status, enrolment and results-posting below reflect ClinicalTrials.gov as of that date.
| Registry activity | Trials |
|---|---|
| trial records updated in the last week | 1 |
| trial records updated in the last month | 6 |
| trial records updated in the last 2 months | 11 |
| trial records updated in the last 3 months | 15 |
| trial records updated in the last 6 months | 21 |
| trial records updated in the last year | 30 |
Recently updated registrations¶
Posted efficacy and safety results¶
Trials whose sponsors have posted results to the registry. Adverse-event figures are participant counts summed across all arms as reported — read them against enrolment, and follow the registry link for the arm-by-arm breakdown that determines whether a signal is real.
| Results posted | Trial | Phase | N | Primary outcome | Serious AE | Other AE | Deaths |
|---|---|---|---|---|---|---|---|
| 2026-07-22 | Sotorasib and Panitumumab Versus Investigator's Choice for Participant | PHASE3 | 160 | Progression-free Survival (PFS) Per Response Evaluation Criteria in So | 46 | 152 | 56 |
| 2026-06-11 | A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in | PHASE3 | 841 | SLI: Number of Participants With Dose Limiting Toxicity (DLTs) | 321 | 790 | 400 |
| 2026-03-03 | Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With | PHASE3 | 455 | Progression-free Survival (PFS) | 174 | 410 | 232 |
| 2025-09-22 | A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Cho | PHASE3 | 839 | Progression-free Survival (PFS) by Blinded Independent Review Center ( | 431 | 807 | 339 |
| 2023-04-18 | Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer | PHASE2 | 117 | Confirmed Objective Response Rate (cORR) Per RECIST v1.1 Per Blinded I | 29 | 133 | 71 |
31 of these trials are still recruiting or active — see the condition's clinical trials page for the full landscape.
Which pages rest on the newest evidence¶
🔥 marks a page citing three or more papers from the last year — the pages worth re-reading if you have been away.
| Page | Newest citation | In last year | Total citations |
|---|---|---|---|
| clinical-trials-landscape | 2026-10-02 | 10 | 29 |
| localized-colon-cancer | 2026-10-02 | 2 | 28 |
| localized-rectal-cancer | 2026-10-02 | 6 | 31 |
| metastatic-systemic-therapy | 2026-10-02 | 4 | 29 |
| precision-oncology | 2026-10-02 | 2 | 27 |
| screening-and-early-detection | 2026-09-17 | 6 | 30 |
| guidelines | 2026-09-03 | 6 | 40 |
| liver-and-lung-metastasis | 2026-09-02 | 5 | 29 |
| biomarkers-and-liquid-biopsy | 2026-09-01 | 3 | 26 |
| hereditary-syndromes-and-genetics | 2026-07-09 | 1 | 27 |
| red-flags-and-safety-concerns | 2026-07-02 | 1 | 26 |
| epidemiology-and-burden | 2026-07-01 | 1 | 26 |
| patient-experience-and-advocacy | 2026-01-02 | 1 | 26 |
| survivorship-and-late-effects | 2025-04-02 | 0 | 26 |
| overview | 2025-01-02 | 0 | 49 |
| molecular-subtypes-and-tumor-microenvironment | 2024-09-04 | 0 | 26 |
| pathology-staging-and-diagnostic-workup | 2024-09-01 | 0 | 25 |
| adenoma-carcinoma-and-serrated-pathways | 2024-03-07 | 0 | 25 |
Recency is not quality: an old paper may be the definitive one, and a new paper may not replicate. Use this to find movement, not to rank evidence. See open questions for what remains unresolved, and the curation log for when these pages were last revised.